Jul 11, 2025 | Comparative Effectiveness, Cost Savings, Drug advertising, Drug costs, Health care costs, High-value formulary, MedBen Rx, Pharmacy, Rx Costs, Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Jul 10, 2025 | Cost Savings, Health care costs, Trend
Per Fierce Healthcare: “A new report from federal actuaries estimates national health spending will increase by 7.1% in 2025, with spending growth set to outpace growth in the U.S. gross domestic product.” Historically, MedBen clients have maintained a cost trend...
Jul 1, 2025 | Cost Savings, Drug costs, GLP-1s, MedBen Rx, Ozempic, Rebates, Rx Costs, Specialty Drugs, Wegovy, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
Jun 27, 2025 | Cost management, Cost Savings, Discounts, Forensic claims review, Health care costs, Savings
The 2025 MedBen Client Report highlights how our proven self-funding solutions have consistently helped employers control health care costs. One of the most impactful tools – forensic claims review – was introduced in 2007 and continues to deliver measurable value,...
Apr 21, 2025 | Biosimilars, Cost Savings, Drug costs, Rx Costs, Savings, Stelara
Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by...
Mar 25, 2025 | Alternative Reimbursement Strategies, Cost Savings, Discounts, Fair market reimbursement, Health care costs
MedBen clients who used Fair Market Reimbursement in 2024 yielded a discount average of 56% with an appeals rate of just 0.23%. MedBen’s Fair Market Reimbursement combines the best aspects of PPOs and reference-based pricing by evaluating all types of claims to...
